Trial Profile
Study of effectiveness and safety of standard dose and low dose rivaroxaban in patients with atrial fibrillation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2018
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Embolism and thrombosis; Stroke
- Focus Adverse reactions; Therapeutic Use
- 29 Aug 2018 Results presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology
- 02 Aug 2018 New trial record
- 31 Jul 2018 Results published in the Journal of the American College of Cardiology